Print Email

Recent Publications by Members of the Neurological Complications Study Group


Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Gait Posture. 2019 Jun;71:62-68.

Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR et al. Brain Behav. 2019 Jun;9(6):e01312. Free PMC Article

Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ, Chan A. Pharmacotherapy. 2019 May;39(5):553-563.

Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Clin Cancer Res. 2019 May 23. [Epub ahead of print] Review.

Neuronal Protection for Chemotherapy Neuropathy Prevention? Loprinzi CL, Hershman DL, Staff N.

J Natl Cancer Inst. 2019 May 15.  [Epub ahead of print]

Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors. Petrovchich I, Kober KM, Wagner L, Paul SM, Abrams G, Chesney MA et al. J Pain Symptom Manage. 2019 Apr 30. [Epub ahead of print]

Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK et al. Support Care Cancer. 2019 Apr 10. [Epub ahead of print]

Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A et al. BMC Cancer. 2019 Feb 8;19(1):132. Free PMC Article

Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors. Wong ML, Cooper BA, Paul SM, Abrams G, Topp K, Kober KM et al. Support Care Cancer. 2019 Feb 15. [Epub ahead of print]

A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, Loprinzi CL. J Palliat Care. 2019 Feb 3:825859719827589. [Epub ahead of print]

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D et al. J Natl Cancer Inst. 2019 Jan 31.[Epub ahead of print]

Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study. Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419828823.

Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. Kober KM, Mazor M, Abrams G, Olshen A, Conley YP, Hammer M, Schumacher M et al. J Pain Symptom Manage. 2018 Dec;56(6):908-919.e3.

Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Griffiths C, Kwon N, Beaumont JL, Paice JA. Support Care Cancer. 2018 Oct;26(10):3461-3469.

Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. Ng T, Phey XY, Yeo HL, Shwe M, Gan YX, Ng R, Ho HK, Chan A. Clin Breast Cancer. 2018 Oct;18(5):e927-e937.

Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. Kim HJ, Barsevick AM, Chan A, Chae JW. Psychooncology. 2018 Aug;27(8):1995-2001.

Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors. Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, Kober KM et al. J Pain Symptom Manage. 2018 Jul;56(1):88-97. Free PMC Article

Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP. J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):636-641. Free PMC Article

Supplements to Help Prevent Neuropathy During Chemotherapy? A Cautionary Tale. Giridhar KV, Viscuse PV, Loprinzi CL, Ruddy KJ. J Natl Cancer Inst. 2018 Jun 1;110(6):551-552.

Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M et al. Psychooncology. 2018 Apr;27(4):1185-1192.

Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX et al. Breast Cancer Res Treat. 2018 Apr;168(3):713-721.

Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life. Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, Kober KM et al. J Cancer Surviv. 2018 Apr;12(2):234-245. Free PMC Article

Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Kober KM, Olshen A, Conley YP, Schumacher M, Topp K, Smoot B. Mol Pain. 2018 Jan-Dec;14:1744806918816462. Free PMC Article

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. Mayo SJ, Kuruvilla J, Laister RC, Ayala AP, Alm M, Byker W, Kelly DL, Saligan L. BMJ Open. 2018 Jan 27;8(1):e017578. Free Article

Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A. Psychooncology. 2018 Jan 9. [Epub ahead of print]

Chemotherapy-Induced Neuropathy in Cancer Survivors. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2.

Chemotherapy-induced neuropathy: Central resolution of a peripherally perceived problem? Cathcart-Rake EJ, Hilliker DR, Loprinzi CL. Cancer. 2017 Jun 1;123(11):1898-1900.

New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment. Majithia N, Loprinzi CL, Smith TJ. Oncology (Williston Park). 2016 Nov 15;30(11).

Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).  Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, et al. Support Care Cancer. 2016 Dec;24(12):5059-5068.

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Exp Toxicol Pathol. 2016 Oct;68(9):505-515.

Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. Jordan B, Jahn F, Beckmann J, Unverzagt S, Müller-Tidow C, Jordan K. Oncology. 2016;90(6):299-306.

Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Boora GK, Kanwar R, Kulkarni AA, Abyzov A, Sloan J, Ruddy KJ, Banck MS, Loprinzi CL, Beutler AS. Cancer Med. 2016 Apr;5(4):631-9.

National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. Support Care Cancer. 2016 Mar;24(3):1439-47.

Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, et al. Clin Colorectal Cancer. 2016 Mar;15(1):37-46.

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. J Clin Oncol. 2015 Oct 20;33(30):3416-22.

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, et al. Support Care Cancer. 2016 Mar;24(3):1071-8.

Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.  Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, Ruddy KJ, Loprinzi CL. Support Care Cancer. 2016 Feb;24(2):547-53.

Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, et al. J Neurol Sci. 2015 Oct 15;357(1-2):35-40.

Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Ann Oncol. 2015 Jul;26(7):1446-51.

Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J,  et al. Support Care Cancer. 2016 Feb;24(2):547-53.

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, et al. Am J Hematol. 2015 Oct;90(10):877-81.

Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, et al. J Neurol Sci. 2015 Oct 15;357(1-2):35-40.

Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Blood. 2015 Jun 4;125(23):3669-71.

Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: Results from a prospective multicenter study. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. J Pain Symptom Manage. 2015 Jun;49(6):1016-24.

Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Ewertz M, Qvortrup C, Eckhoff L.  Acta Oncol. 2015 May;54(5):587-91.

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ et al. Support Care Cancer. 2015 Apr;23(4):943-51.

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, et al. Support Care Cancer. 2015 Apr;23(4):943-51.

Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK.  Acta Oncol. 2015 Apr;54(4):530-7.

Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Eur J Cancer. 2015 Mar;51(4):437-50.

Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. J Cancer Surviv. 2015 Mar;9(1):1-10.

Chemotherapy-induced neuropathy—Where are we now? Ruddy, KJ, Majithia, N, Pachman DR, Beutler AS, Loprinzi CL. Oncology & Hematology Review, Spring 2015;11(1):53–5.

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eckhoff L, Knoop A, Jensen M, Ewertz M.  Eur J Cancer. 2015 Feb;51(3):292-300.

Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P.  J Neurol Sci. 2015 Feb 15;349(1-2):124-8.

The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Ng T, Khor CC, Ho HK, Chan A.  Cancer Treatment Reviews 2014; Dec;40(10):1199-1214.

Therapeutic strategies for cancer treatment related peripheral neuropathies. Pachman DR, Watson JC, Loprinzi CL. Curr Treat Options Oncol. 2014 Dec;15(4):567-80.

Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK.  Acta Oncol. 2014 Nov 10:1-8.

Management options for established chemotherapy-induced peripheral neuropathy. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, et al. Support Care Cancer. 2014 Aug;22(8):2281-95.

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. J Clin Epidemiology 2014; Jul;67(7):811-20.

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.  Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology.Cancer. 2014 Jun 15;120(12):1890-7.

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. J Clin Oncol. 2014 Apr 1;32(10):997-1005.